Skip to main content
SpringerLink
Log in

Neuroendokrine Neoplasien des Pankreas

Pancreatic neuroendocrine neoplasms

  • Leitthema
  • Published:
Der Radiologe Aims and scope Submit manuscript

Zusammenfassung

Neuroendokrine Neoplasien (NEN) des Pankreas stellen mit einem Anteil von 1–2 % aller pankreatischen Tumoren eine seltene Differenzialdiagnose dar. Ein Teil der Tumoren ist hormonell aktiv und fällt klinisch durch charakteristische Symptome auf, wohingegen der überwiegende Anteil hormonell inaktiv ist. Bildgebende Verfahren wie Sonographie, Computertomographie (CT), Magnetresonanztomographie (MRT) und nicht zuletzt Positronenemissionstomographie (PET oder kombiniert als PET/CT) spielen eine zentrale Rolle für Erstdiagnose, Therapieplanung und -kontrolle. Die Endosonographie und die multiphasische CT stellen die Referenzmethoden zur Lokalisation des Primärtumors dar. Für die Differenzierung insbesondere kleiner Leberläsionen bietet die MRT die höchste Aussagekraft. Für das Ganzkörperstaging und bestimmte Aspekte der Therapieplanung lassen sich die Somatostatinrezeptorszintigraphie und v. a. die Somatostatinrezeptor-PET/CT heranziehen.

Abstract

Pancreatic neuroendocrine neoplasms (NEN) account for 1–2 % of all pancreatic neoplasms and represent a rare differential diagnosis. While some pancreatic NEN are hormonally active and exhibit endocrine activity associated with characteristic symptoms, the majority are hormonally inactive. Imaging techniques such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) or as combined PET/CT play a crucial role in the initial diagnosis, therapy planning and control. Endoscopic ultrasound (EUS) and multiphase CT represent the reference methods for localization of the primary pancreatic tumor. Particularly in the evaluation of small liver lesions MRI is the method of choice. Somatostatin receptor scintigraphy and somatostatin receptor PET/CT are of particular value for whole body staging and special aspects of further therapy planning.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Oberg K, Eriksson B (2005) Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19:753–781. doi:10.1016/j.bpg.2005.06.002

    Article  PubMed  Google Scholar 

  2. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM (2008) Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 15(2):409–427. doi:10.1677/ERC-07-0221

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kimura W, Kuroda A, Morioka Y (1991) Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 36(7):933–942

    Article  CAS  PubMed  Google Scholar 

  4. Kloppel G (2001) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 17(18 Suppl):S1–16. doi:10.1530/ERC-11-0013

    Google Scholar 

  5. Capelli P, Fassan M, Scarpa A (2012) Pathology – grading and staging of GEP-NETs. Best Pract Res Clin Gastroenterol 26(6):705–717. doi:10.1016/j.bpg.2013.01.003

    Article  PubMed  Google Scholar 

  6. Begum N, Maasberg S, Plockinger U et al (2014) Neuroendocrine tumours of the GI tract–data from the German NET Registry. Zentralbl Chir 139(3):276–283. doi:10.1055/s-0032-1315199

    PubMed  Google Scholar 

  7. Balachandran A, Tamm EP, Bhosale PR et al (2012) Pancreatic neuroendocrine neoplasms: diagnosis and management. Abdom Imaging 38(2):342–357. doi:10.1007/s00261-012-9923-1

    Article  Google Scholar 

  8. Beger HG, Büchler MW, Dralle H, Lerch MM, Malfertheiner P, Mössner J et al (2013) Erkrankungen des Pankreas. Springer, Berlin, Heidelberg

    Book  Google Scholar 

  9. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781–793. doi:10.1007/s00259-003-1184-3

    Article  CAS  PubMed  Google Scholar 

  10. Pape U, Berndt U, Muller-Nordhorn J et al (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15:1083–1097. doi:10.1677/ERC-08-0017

    Article  PubMed  Google Scholar 

  11. Falconi M, Plockinger U, Kwekkeboom DJ et al (2006) Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 84:196–211. doi:10.1159/000098012

    Article  CAS  PubMed  Google Scholar 

  12. Campana D, Nori F, Piscitelli L et al (2007) Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25(15):1967–1973. doi:10.1200/JCO.2006.10.1535

    Article  CAS  PubMed  Google Scholar 

  13. Okabayashi T, Shima Y, Sumiyoshi T et al (2013) Diagnosis and management of insulinoma. World J Gastroenterol 19(6):829–837. doi:10.3748/wjg.v19.i6.829

    Article  PubMed  PubMed Central  Google Scholar 

  14. de Herder WW, Niederle B, Scoazec J et al (2006) Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 84:183–188. doi:10.1159/000098010

    Article  PubMed  Google Scholar 

  15. Sundin A, Vullierme M, Kaltsas G, Plockinger U (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 90:167–183. doi:10.1159/000184855

    Article  CAS  PubMed  Google Scholar 

  16. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC (1998) Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 206:143–150. doi:10.1148/radiology.206.1.9423664

    Article  CAS  PubMed  Google Scholar 

  17. Miwa H, Numata K, Sugimori K et al (2014) Differential diagnosis of solid pancreatic lesions using contrast-enhanced three-dimensional ultrasonography. Abdom Imaging 39(5):988–999. doi:10.1007/s00261-014-0135-8

    Article  PubMed  PubMed Central  Google Scholar 

  18. Khashab MA, Yong E, Lennon AM et al (2011) EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 73(4):691–696. doi:10.1016/j.gie.2010.08.030

    Article  PubMed  Google Scholar 

  19. Mork H, Ignee A, Schuessler G, Ott M, Dietrich CF (2007) Analysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography. Scand J Gastroenterol 42(5):652–662. doi:10.1080/00365520601021765

    Article  PubMed  Google Scholar 

  20. Albanus DR, Apitzsch J, Erdem Z et al (2015) Clinical value of (68)Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET). Eur J Radiol 84(10):1866–1872. doi:10.1016/j.ejrad.2015.06.024

    Article  CAS  PubMed  Google Scholar 

  21. Khalil HI, Patterson SA, Panicek DM (2005) Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. Radiology 235:872–878. doi:10.1148/radiol.2353041099

    Article  PubMed  Google Scholar 

  22. Schraml C, Schwenzer NF, Sperling O et al (2013) Staging of neuroendocrine tumours: comparison of (6)(8)GaDOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging 13(1):63–72. doi:10.1102/1470-7330.2013.0007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lowenthal D, Zeile M, Lim WY et al (2011) Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol 21:832–840. doi:10.1007/s00330-010-1977-2

    Article  CAS  PubMed  Google Scholar 

  24. Bottcher J, Hansch A, Pfeil A et al (2013) Detection and classification of different liver lesions: Comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic spiral CT in a clinical single centre investigation. Eur J Radiol 82:1860–1869. doi:10.1016/j.ejrad.2013.06.013

    Article  PubMed  Google Scholar 

  25. Wu L, Gu H, Zheng J et al (2011) Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis. J Magn Reson Imaging 34:128–135. doi:10.1002/jmri.22608

    Article  PubMed  Google Scholar 

  26. Reubi JC, Schar JC, Waser B et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3):273–282

    Article  CAS  PubMed  Google Scholar 

  27. Kwekkeboom DJ, Kam BL, van Essen M et al (2010) Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17(1):R53–R73. doi:10.1677/ERC-09-0078

    Article  CAS  PubMed  Google Scholar 

  28. Teunissen JJM, Kwekkeboom DJ, Valkema R, Krenning EP (2011) Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer 18(Suppl 1):S27–S51. doi:10.1530/ERC-10-0282

    Article  CAS  PubMed  Google Scholar 

  29. Koopmans KP, Neels ON, Kema IP et al (2009) Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol 71:199–213. doi:10.1016/j.critrevonc.2009.02.009

    Article  PubMed  Google Scholar 

  30. Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36:228–247. doi:10.1053/j.semnuclmed.2006.03.007

    Article  PubMed  Google Scholar 

  31. Naswa N, Sharma P, Gupta SK et al (2014) Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68 Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Clin Nucl Med 39(1):e27–e34. doi:10.1097/RLU.0b013e31827a216b

    Article  PubMed  Google Scholar 

  32. Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V et al (2013) Simultaneous 68 Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol 48(5):273–279. doi:10.1097/RLI.0b013e3182871a7

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Universitätsklinikum Essen, Hufelandstrasse 55, 45147, Essen, Deutschland

    K. Beiderwellen & T. C. Lauenstein

  2. Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstrasse 55, 45147, Essen, Deutschland

    A. Sabet & T. D. Poeppel

  3. Klinik für Endokrinologie und Stoffwechselerkrankungen, Universitätsklinikum Essen, Hufelandstrasse 55, 45147, Essen, Deutschland

    H. Lahner

Authors
  1. K. Beiderwellen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Sabet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. C. Lauenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Lahner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. D. Poeppel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Beiderwellen.

Ethics declarations

Interessenkonflikt

K. Beiderwellen, A. Sabet, T. Lauenstein, H. Lahner und T. Poeppel geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beiderwellen, K., Sabet, A., Lauenstein, T.C. et al. Neuroendokrine Neoplasien des Pankreas. Radiologe 56, 348–354 (2016). https://doi.org/10.1007/s00117-016-0094-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00117-016-0094-x

Schlüsselwörter

Keywords

Search

Navigation